Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Annals of the New York Academy of Sciences|June 20, 2003
How proteases regulate bone morphogenesisNathalie Ortega, Danielle Behonick, Dominique Stickens, et al.Development (Cambridge, England)|October 21, 2005
Mice deficient in Ext2 lack heparan sulfate and develop exostosesDominique Stickens, Beverly M Zak, Nathalie Rougier, et al.Mitochondrion|February 20, 2018
PPARδ modulation rescues mitochondrial fatty acid oxidation defects in the mdx model of muscular dystrophyEric L Bell, Robert W Shine, Peter Dwyer, et al.The Journal of Investigative Dermatology|December 24, 2005
Epidermal development and wound healing in matrix metalloproteinase 13-deficient miceBettina Hartenstein, Bernd Thilo Dittrich, Dominique Stickens, et al.Nucleic Acid Therapeutics|October 2, 2014
A single dose of EGLN1 siRNA yields increased erythropoiesis in nonhuman primatesMarc T Abrams, Martin Koser, Julja Burchard, et al.Development (Cambridge, England)|November 13, 2004
Altered endochondral bone development in matrix metalloproteinase 13-deficient miceDominique Stickens, Danielle J Behonick, Nathalie Ortega, et al.Journal of Medicinal Chemistry|December 23, 2016
Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of AnemiaJohn S Debenham, Christina Madsen-Duggan, Matthew J Clements, et al.ACS Medicinal Chemistry Letters|January 8, 2019
Discovery of Orally Bioavailable and Liver-Targeted Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PHD) Inhibitors for the Treatment of AnemiaPing Liu, Liping Wang, Byron G DuBois, et al.Pageof 1